Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma

Journal of Surgical Oncology

Volumn 100, Issue 6, 2009, Pages 494-499

  Furukawa, Hiroyoshi ^a   Ikuma, Hiroki ^a   Asakura, Koiku ^a   Uesaka, Katsuhiko ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Biliary neoplasms; F 18 fluorodeoxyglucose; Positron emission tomography; Prognostic factor; TNM staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT BIOPSY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 70350345016     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21356     Document Type: Article

References (30)

1. Kluge R, Schmidt F, Caca K, et al.: Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-1035. (Pubitemid 32378198)
2. Kato T, Tsukamoto E, Kuge Y, et al.: Clinical role of 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med 2002;29:1047-1054. (Pubitemid 44298187)
3. Kim YJ, Yun M, Lee WJ, et al.: Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003;30:1467-1472. (Pubitemid 37356113)
4. Reinhardt MJ, Strunk H, Gerhardt T, et al.: Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: Preliminary results for 22 patient studies. J Nucl Med 2005;46:1158-1163. (Pubitemid 43741078)
5. Petrowsky H, Wildbrett P, Husarik DB, et al.: Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43-50. (Pubitemid 43850623)
6. Kim JY, Kim MH, Lee TY, et al.: Clinical role of 18F-FDG PETCT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145-1151.
7. Furukawa H, Ikuma H, Asakura K, et al.: Preoperative staging of biliary carcinoma using 18F-fluorodeoxyglucose PET: Prospective comparison with PET + CT, MDCT and histopathology. Eur Radiol 2008;18:2841-2847.
8. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al.: Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. J Clin Oncol 1999;17:3201-3206.
9. Downey RJ, Akhurst T, Gonen M, et al.: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-3260. (Pubitemid 41103680)
10. Cerfolio RJ, Bryant AS, MSPH MD: Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006;82:391-395. (Pubitemid 44080040)
11. Sasaki R, Komaki R, Macapinlac H, et al.: [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-1143. (Pubitemid 46202269)
12. Oshida M, Uno K, Suzuki M, et al.: Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer 1998;82:2227-2234.
13. Minn H, Lapela M, Klemi PJ, et al.: Prediction of survival with fluorin-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907-1911. (Pubitemid 28030920)
14. Hatano E, Ikai I, Higashi T, et al.: Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736-1741. (Pubitemid 44411232)
15. Cerfolio RJ, Bryant AS, Ohja B, et al.: The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-159. (Pubitemid 40941684)
16. vanWestreenen HL, Plukker JTM, Cobben DCP, et al.: Prognostic value of the standardized uptake value in esophageal cancer. Am J Roentgenol 2005;185:436-440.
17. Choi JY, Jang KT, Shim YM, et al.: Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol 2006;13:1054-1062.
18. Mochiki E, Kuwano H, Katoh H, et al.: Evaluation of 18F-2-deoxy-2-fluoro- D-glucose positron emission tomography for gastric cancer. World J. Surg 2004;28:247-253. (Pubitemid 38375523)
19. Stahl A, Ott K, Weber WA, et al.: FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histological findings. Eur J Nucl Med 2003;30:288-295. (Pubitemid 36686849)
20. Sobin LH, Wittekind C: TNM Classification of malignant tumours. 6th edition. New York: Wiley & Sons; 2003.
21. Bos R, Van Der Hoeven JJ, Van Der Wall E, et al.: Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-387. (Pubitemid 34072519)
22. Kurokawa T, Yoshida Y, Kawahara K, et al.: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 2004;109:926-932. (Pubitemid 38500750)
23. Chung JK, Lee YJ, Kim SK, et al.: Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 2004;25:11-17.
24. Paudyal B, Oriuchi N, Paudyal P, et al.: Expression of glucose transporters and hexokinase II in cholangiocarcinoma compared using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 2008;99:260-266.
25. Lee JD, Yang WI, Park YN, et al.: Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med 2005;46:1753-1759.
26. Younes M, Lechago LV, Lechago J: Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 1996;2:1151-1154. (Pubitemid 26238445)
27. Kawamura T, Kusakabe T, Sugino T, et al.: Expression of glucose transporter-1 in human gastric carcinoma - association with tumor aggressiveness, metastasis, and patient survival. Cancer 2001;92:634-641. (Pubitemid 32735200)
28. Gu J, Yamamoto H, Fukunaga H, et al.: Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006;51:2198-2205.
29. Furudoi A, Tanaka S, Haruma K, et al.: Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001;60:162-169. (Pubitemid 32245335)
30. Minn H, Zasadny KR, Quint LE, et al.: Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-D-glucose uptake at PET. Radiology 1995;196:167-173.